Biohaven Ltd. (BHVN): Total Assets
$451.45M
As of 2025-12-31
$370.74M
As of 2026-06-30
-12.0%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $451.45M | -26.6% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $615.11M | +19.9% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $513.21M | -22.5% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $661.78M | +365.8% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $142.06M | n/a | 2023-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Biohaven Ltd. (BHVN) | 2025-12-31 | $451.45M | -26.6% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $448.38M | +172.9% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $433.81M | +718.5% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $432.97M | +24.1% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $430.99M | -15.5% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $476.17M | +46.2% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $479.51M | +250.2% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $424.43M | -11.2% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
Compare BHVN, BBOT, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗